tradingkey.logo

Renovaro Inc

RENB
查看詳細走勢圖
1.420USD
0.000
收盤 12/22, 16:00美東報價延遲15分鐘
251.90M總市值
虧損本益比TTM

Renovaro Inc

1.420
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

0.00%

1月

0.00%

6月

+315.93%

今年開始到現在

+69.96%

1年

-13.41%

查看詳細走勢圖

TradingKey Renovaro Inc股票評分

單位: USD 更新時間: 2025-09-30

操作建議

Renovaro Inc當前公司基本面數據相對謹慎,當前估值合理,機構持股佔比非常高,近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Renovaro Inc評分

相關信息

行業排名
259 / 505
全市場排名
431 / 4713
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Renovaro Inc亮點

亮點風險
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
估值低估
公司最新PE估值-5.82,處於3年歷史低位
機構加倉
最新機構持股65.41M股,環比增加6.49%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉4.92M股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.33

Renovaro Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Renovaro Inc簡介

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
公司代碼RENB
公司Renovaro Inc
CEOWeinstein (David)
網址

常見問題

Renovaro Inc(RENB)的當前股價是多少?

Renovaro Inc(RENB)的當前股價是 1.420。

Renovaro Inc 的股票代碼是什麼?

Renovaro Inc的股票代碼是RENB。

Renovaro Inc股票的52週最高點是多少?

Renovaro Inc股票的52週最高點是21.000。

Renovaro Inc股票的52週最低點是多少?

Renovaro Inc股票的52週最低點是1.130。

Renovaro Inc的市值是多少?

Renovaro Inc的市值是251.90M。

Renovaro Inc的淨利潤是多少?

Renovaro Inc的淨利潤為-178.01M。

現在Renovaro Inc(RENB)的股票是買入、持有還是賣出?

根據分析師評級,Renovaro Inc(RENB)的總體評級為--,目標價格為--。

Renovaro Inc(RENB)股票的每股收益(EPS TTM)是多少

Renovaro Inc(RENB)股票的每股收益(EPS TTM)是-0.244。
KeyAI